ISDA

Deposition Date 2023-06-13

Release Date 2024-01-10

Last Version Date 2024-01-24

Entry Detail

PDB ID:

8T5G

Keywords:

SIGNALING PROTEIN

Title:

SOS2 co-crystal structure with fragment bound (compound 12)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.92 Å

R-Value Free:

0.24

R-Value Work:

0.19

R-Value Observed:

0.20

Space Group:

P 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Son of sevenless homolog 2
Gene (Uniprot):SOS2
Chain IDs:A
Chain Length:490
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q07890 Pfam ID:PF00618, PF00617

Ligand Molecules

DMS

SO4

THA

Primary Citation

Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.

Smith, C.R, Chen, D, Christensen, J.G, Coulombe, R, Fethiere, J, Gunn, R.J, Hollander, J, Jones, B, Ketcham, J.M, Khare, S, Kuehler, J, Lawson, J.D, Marx, M.A, Olson, P, Pearson, K.E, Ren, C, Tsagris, D, Ulaganathan, T, Van't Veer, I, Wang, X, Ivetac, A.Show

J.Med.Chem. 67 774 781 (2024)

PMID: 38156904 DOI: 10.1021/acs.jmedchem.3c02140

Abstact

SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of SOS2:KRAS PPI inhibitors. SOS2 activity is implicated in MAPK rebound when divergent SOS1 mutant cell lines are treated with the SOS1 inhibitor BI-3406; therefore, SOS2:KRAS inhibitors are of therapeutic interest. In this report, we detail a fragment-based screening strategy to identify X-ray cocrystal structures of five diverse fragment hits bound to SOS2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures